Onconetix appoints James Sapirstein as Executive Chairman; former Interim CEO resigns

Onconetix, Inc.

Dr. Ralph Schiess resigned as Interim CEO and CSO effective Feb 24, 2025; also to leave Proteomedix AG CEO role on May 31, 2025.
James Sapirstein, existing Board member, appointed Executive Chairman; he is also CEO of Entero Therapeutics (Nasdaq: ENTO).
Sapirstein compensated $400/hour for up to 20 hours/week; payment contingent on company securing sufficient capital.
Board expanded from five to six; Andrew Oakley appointed as Class II director; former CFO at Autolus, Sosei, Vectura, Actelion.

item 1.01 item 5.02 item 5.08 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Oakley

Class II director

ONCO · Onconetix, Inc.

Effective: 2025-02-24
Filed: February 28, 2025, 6:59 PM ET

On February 24, 2025, the Board approved an increase to the Board’s size from five to six members and appointed Andrew Oakley, 62, to fill the new Board seat as a Class II director

Role change

James Sapirstein

Executive Chairman

ONCO · Onconetix, Inc.

Effective: 2025-02-24
Filed: February 28, 2025, 6:59 PM ET

On February 24, 2025, the Company’s Board of Directors (the “Board”) appointed James Sapirstein, 63, an existing member of the Board, as Executive Chairman.

Departed

Ralph Schiess

Interim Chief Executive Officer and Chief Science Officer

ONCO · Onconetix, Inc.

Effective: 2025-02-24
Filed: February 28, 2025, 6:59 PM ET

On February 24, 2025, Dr. Ralph Schiess resigned from his positions as the Interim Chief Executive Officer and Chief Science Officer of Onconetix, Inc. (the “Company”), effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Oakley was appointed as Class II director at Onconetix, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

On February 24, 2025, the Board approved an increase to the Board’s size from five to six members and appointed Andrew Oakley, 62, to fill the new Board seat as a Class II director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Sapirstein was appointed as Executive Chairman at Onconetix, Inc..

Action: appointed
Role: Executive Chairman

Exact text from the filing

On February 24, 2025, the Company’s Board of Directors (the “Board”) appointed James Sapirstein, 63, an existing member of the Board, as Executive Chairman.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ralph Schiess resigned as Interim Chief Executive Officer and Chief Science Officer at Onconetix, Inc..

Action: resigned
Role: Interim Chief Executive Officer and Chief Science Officer

Exact text from the filing

On February 24, 2025, Dr. Ralph Schiess resigned from his positions as the Interim Chief Executive Officer and Chief Science Officer of Onconetix, Inc. (the “Company”), effective immediately

View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-018867

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.